Debbie Bowen-Heaton, partner at Oliver Wight, provides an Expert View on how companies can prepare for the disruption Amazon's arrival in Europe's pharmaceutical space will bring.
Following its successful launch in the USA, Amazon applied for ‘Amazon Pharmacy’ trademarks in the UK and European Union (EU) last year.
Together with Amazon’s partnership with the National Health Service (NHS) in the UK, to offer medical advice on its platform Alexa, this is systematic of the way in which Amazon is looking to disrupt and revolutionize the sector.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze